The Amgen presented the results of trials of a new drug against bronchial asthma. The tool is called the AMG 157 is an inhibitor of thymic stromal lymphopoietin (TSLP). The drug inhibits the synthesis of epithelial cells, and is an important part of the immune response of the body.
The agent is an antibody that communicates with lymphopoietin that does not allow him to have contact with the receptor.
AMG 157 experienced in 31 patients with atopic bronchial asthma of moderate severity. Each patient received three injections of the drug or a placebo. Next, the researchers measured forced expiratory volume per second. Also evaluated the nitrogen concentration in the exhaled air and the number of eosinophils in sputum and blood.
After 42 days of treatment in the main group rate forced expiratory volume was 34% better than in the placebo group. After three months the figure was better 45.9%. It is very important that side effects during the trials of the drug were noted. Now experts are preparing to conduct a series of tests of the effectiveness of the drug in patients with severe bronchial asthma.